id	sid	tid	token	lemma	pos
egc-239	1	1	eglobal	eglobal	PROPN
egc-239	1	2	congress	congress	PROPN
egc-239	1	3	hosted	host	VERB
egc-239	1	4	online	online	ADV
egc-239	1	5	from	from	ADP
egc-239	1	6	dubai	dubai	PROPN
egc-239	1	7	,	,	PUNCT
egc-239	1	8	u.	u.	PROPN
egc-239	1	9	a.	a.	PROPN
egc-239	1	10	e.	e.	PROPN
egc-239	1	11	,	,	PUNCT
egc-239	1	12	e	e	PROPN
egc-239	1	13	conference	conference	NOUN
egc-239	1	14	.	.	PUNCT
egc-239	2	1	date	date	NOUN
egc-239	2	2	:	:	PUNCT
egc-239	2	3	29th	29th	ADJ
egc-239	2	4	september	september	PROPN
egc-239	2	5	2024	2024	NUM
egc-239	2	6	website	website	NOUN
egc-239	2	7	:	:	PUNCT
egc-239	2	8	https://eglobalcongress.com/index.php/egc	https://eglobalcongress.com/index.php/egc	PROPN
egc-239	2	9	issn	issn	PROPN
egc-239	2	10	(	(	PUNCT
egc-239	2	11	e	e	NOUN
egc-239	2	12	):	):	PUNCT
egc-239	2	13	2836	2836	NUM
egc-239	2	14	-	-	SYM
egc-239	2	15	3612	3612	NUM
egc-239	2	16	12	12	NUM
egc-239	3	1	|	|	ADV
egc-239	3	2	p	p	ADP
egc-239	3	3	a	a	DET
egc-239	3	4	g	g	NOUN
egc-239	3	5	e	e	NOUN
egc-239	3	6	correlation	correlation	NOUN
egc-239	3	7	of	of	ADP
egc-239	3	8	cytokine	cytokine	ADJ
egc-239	3	9	levels	level	NOUN
egc-239	3	10	in	in	ADP
egc-239	3	11	children	child	NOUN
egc-239	3	12	with	with	ADP
egc-239	3	13	juvenile	juvenile	ADJ
egc-239	3	14	rheumatoid	rheumatoid	NOUN
egc-239	3	15	arthritis	arthritis	NOUN
egc-239	3	16	(	(	PUNCT
egc-239	3	17	jra	jra	PROPN
egc-239	3	18	)	)	PUNCT
egc-239	3	19	aged	aged	ADJ
egc-239	3	20	7	7	NUM
egc-239	3	21	to	to	PART
egc-239	3	22	14	14	NUM
egc-239	3	23	years	year	NOUN
egc-239	3	24	sadikova	sadikova	VERB
egc-239	3	25	a.	a.	NOUN
egc-239	3	26	m.	m.	PROPN
egc-239	3	27	m.	m.	PROPN
egc-239	3	28	r.	r.	PROPN
egc-239	3	29	ruzibakiyeva	ruzibakiyeva	PROPN
egc-239	3	30	tashkent	tashkent	PROPN
egc-239	3	31	pediatric	pediatric	PROPN
egc-239	3	32	medical	medical	PROPN
egc-239	3	33	institute	institute	NOUN
egc-239	3	34	relevance	relevance	NOUN
egc-239	3	35	:	:	PUNCT
egc-239	3	36	juvenile	juvenile	ADJ
egc-239	3	37	rheumatoid	rheumatoid	NOUN
egc-239	3	38	arthritis	arthritis	NOUN
egc-239	3	39	(	(	PUNCT
egc-239	3	40	jra	jra	PROPN
egc-239	3	41	)	)	PUNCT
egc-239	3	42	is	be	AUX
egc-239	3	43	one	one	NUM
egc-239	3	44	of	of	ADP
egc-239	3	45	the	the	DET
egc-239	3	46	most	most	ADV
egc-239	3	47	common	common	ADJ
egc-239	3	48	chronic	chronic	ADJ
egc-239	3	49	inflammatory	inflammatory	ADJ
egc-239	3	50	joint	joint	ADJ
egc-239	3	51	diseases	disease	NOUN
egc-239	3	52	in	in	ADP
egc-239	3	53	children	child	NOUN
egc-239	3	54	,	,	PUNCT
egc-239	3	55	leading	lead	VERB
egc-239	3	56	to	to	ADP
egc-239	3	57	significant	significant	ADJ
egc-239	3	58	immune	immune	ADJ
egc-239	3	59	system	system	NOUN
egc-239	3	60	changes	change	NOUN
egc-239	3	61	.	.	PUNCT
egc-239	4	1	cytokines	cytokine	NOUN
egc-239	4	2	play	play	VERB
egc-239	4	3	a	a	DET
egc-239	4	4	key	key	ADJ
egc-239	4	5	role	role	NOUN
egc-239	4	6	in	in	ADP
egc-239	4	7	the	the	DET
egc-239	4	8	pathogenesis	pathogenesis	NOUN
egc-239	4	9	of	of	ADP
egc-239	4	10	jra	jra	PROPN
egc-239	4	11	,	,	PUNCT
egc-239	4	12	and	and	CCONJ
egc-239	4	13	their	their	PRON
egc-239	4	14	levels	level	NOUN
egc-239	4	15	may	may	AUX
egc-239	4	16	serve	serve	VERB
egc-239	4	17	as	as	ADP
egc-239	4	18	prognostic	prognostic	ADJ
egc-239	4	19	markers	marker	NOUN
egc-239	4	20	for	for	ADP
egc-239	4	21	disease	disease	NOUN
egc-239	4	22	activity	activity	NOUN
egc-239	4	23	.	.	PUNCT
egc-239	5	1	objective	objective	NOUN
egc-239	5	2	:	:	PUNCT
egc-239	5	3	to	to	PART
egc-239	5	4	assess	assess	VERB
egc-239	5	5	the	the	DET
egc-239	5	6	levels	level	NOUN
egc-239	5	7	of	of	ADP
egc-239	5	8	il-8	il-8	NOUN
egc-239	5	9	,	,	PUNCT
egc-239	5	10	il-17a	il-17a	PROPN
egc-239	5	11	,	,	PUNCT
egc-239	5	12	and	and	CCONJ
egc-239	5	13	interferon	interferon	ADJ
egc-239	5	14	-	-	PUNCT
egc-239	5	15	γ	γ	NOUN
egc-239	5	16	(	(	PUNCT
egc-239	5	17	ifnγ	ifnγ	NOUN
egc-239	5	18	)	)	PUNCT
egc-239	5	19	in	in	ADP
egc-239	5	20	children	child	NOUN
egc-239	5	21	with	with	ADP
egc-239	5	22	jra	jra	PROPN
egc-239	5	23	aged	age	VERB
egc-239	5	24	7	7	NUM
egc-239	5	25	to	to	PART
egc-239	5	26	14	14	NUM
egc-239	5	27	years	year	NOUN
egc-239	5	28	,	,	PUNCT
egc-239	5	29	with	with	ADP
egc-239	5	30	both	both	CCONJ
egc-239	5	31	seropositive	seropositive	ADJ
egc-239	5	32	and	and	CCONJ
egc-239	5	33	seronegative	seronegative	ADJ
egc-239	5	34	forms	form	NOUN
egc-239	5	35	of	of	ADP
egc-239	5	36	the	the	DET
egc-239	5	37	disease	disease	NOUN
egc-239	5	38	.	.	PUNCT
egc-239	6	1	materials	material	NOUN
egc-239	6	2	and	and	CCONJ
egc-239	6	3	methods	method	NOUN
egc-239	6	4	:	:	PUNCT
egc-239	6	5	ninety	ninety	NUM
egc-239	6	6	-	-	PUNCT
egc-239	6	7	three	three	NUM
egc-239	6	8	children	child	NOUN
egc-239	6	9	with	with	ADP
egc-239	6	10	jra	jra	PROPN
egc-239	6	11	were	be	AUX
egc-239	6	12	divided	divide	VERB
egc-239	6	13	into	into	ADP
egc-239	6	14	two	two	NUM
egc-239	6	15	age	age	NOUN
egc-239	6	16	groups	group	NOUN
egc-239	6	17	.	.	PUNCT
egc-239	7	1	cytokine	cytokine	ADJ
egc-239	7	2	levels	level	NOUN
egc-239	7	3	were	be	AUX
egc-239	7	4	quantitatively	quantitatively	ADV
egc-239	7	5	assessed	assess	VERB
egc-239	7	6	using	use	VERB
egc-239	7	7	enzyme	enzyme	NOUN
egc-239	7	8	-	-	PUNCT
egc-239	7	9	linked	link	VERB
egc-239	7	10	immunosorbent	immunosorbent	NOUN
egc-239	7	11	assay	assay	PROPN
egc-239	7	12	(	(	PUNCT
egc-239	7	13	elisa	elisa	NOUN
egc-239	7	14	)	)	PUNCT
egc-239	7	15	.	.	PUNCT
egc-239	8	1	results	result	NOUN
egc-239	8	2	and	and	CCONJ
egc-239	8	3	discussion	discussion	NOUN
egc-239	8	4	:	:	PUNCT
egc-239	8	5	il-8	il-8	VERB
egc-239	8	6	levels	level	NOUN
egc-239	8	7	were	be	AUX
egc-239	8	8	significantly	significantly	ADV
egc-239	8	9	elevated	elevate	VERB
egc-239	8	10	in	in	ADP
egc-239	8	11	children	child	NOUN
egc-239	8	12	with	with	ADP
egc-239	8	13	the	the	DET
egc-239	8	14	seropositive	seropositive	ADJ
egc-239	8	15	form	form	NOUN
egc-239	8	16	of	of	ADP
egc-239	8	17	jra	jra	PROPN
egc-239	8	18	(	(	PUNCT
egc-239	8	19	20,9±3,12	20,9±3,12	PROPN
egc-239	8	20	pg	pg	NOUN
egc-239	8	21	/	/	SYM
egc-239	8	22	ml	ml	VERB
egc-239	8	23	)	)	PUNCT
egc-239	8	24	,	,	PUNCT
egc-239	8	25	which	which	PRON
egc-239	8	26	is	be	AUX
egc-239	8	27	1,85	1,85	NUM
egc-239	8	28	times	time	NOUN
egc-239	8	29	higher	high	ADJ
egc-239	8	30	than	than	ADP
egc-239	8	31	in	in	ADP
egc-239	8	32	the	the	DET
egc-239	8	33	control	control	NOUN
egc-239	8	34	group	group	NOUN
egc-239	8	35	.	.	PUNCT
egc-239	9	1	il17a	il17a	PROPN
egc-239	9	2	was	be	AUX
egc-239	9	3	also	also	ADV
egc-239	9	4	significantly	significantly	ADV
egc-239	9	5	elevated	elevate	VERB
egc-239	9	6	in	in	ADP
egc-239	9	7	the	the	DET
egc-239	9	8	seropositive	seropositive	ADJ
egc-239	9	9	group	group	NOUN
egc-239	9	10	(	(	PUNCT
egc-239	9	11	30,25±4,61	30,25±4,61	NUM
egc-239	9	12	pg	pg	ADJ
egc-239	9	13	/	/	SYM
egc-239	9	14	ml	ml	VERB
egc-239	9	15	)	)	PUNCT
egc-239	9	16	,	,	PUNCT
egc-239	9	17	2,88	2,88	NUM
egc-239	9	18	times	time	NOUN
egc-239	9	19	higher	high	ADJ
egc-239	9	20	than	than	ADP
egc-239	9	21	in	in	ADP
egc-239	9	22	the	the	DET
egc-239	9	23	control	control	NOUN
egc-239	9	24	group	group	NOUN
egc-239	9	25	.	.	PUNCT
egc-239	10	1	both	both	DET
egc-239	10	2	groups	group	NOUN
egc-239	10	3	exhibited	exhibit	VERB
egc-239	10	4	a	a	DET
egc-239	10	5	significant	significant	ADJ
egc-239	10	6	reduction	reduction	NOUN
egc-239	10	7	in	in	ADP
egc-239	10	8	ifnγ	ifnγ	NOUN
egc-239	10	9	production	production	NOUN
egc-239	10	10	,	,	PUNCT
egc-239	10	11	particularly	particularly	ADV
egc-239	10	12	in	in	ADP
egc-239	10	13	the	the	DET
egc-239	10	14	seropositive	seropositive	ADJ
egc-239	10	15	group	group	NOUN
egc-239	10	16	,	,	PUNCT
egc-239	10	17	suggesting	suggest	VERB
egc-239	10	18	impaired	impaired	ADJ
egc-239	10	19	antiviral	antiviral	ADJ
egc-239	10	20	defense	defense	NOUN
egc-239	10	21	and	and	CCONJ
egc-239	10	22	activation	activation	NOUN
egc-239	10	23	of	of	ADP
egc-239	10	24	inflammatory	inflammatory	ADJ
egc-239	10	25	pathways	pathway	NOUN
egc-239	10	26	.	.	PUNCT
egc-239	11	1	conclusion	conclusion	NOUN
egc-239	11	2	:	:	PUNCT
egc-239	11	3	the	the	DET
egc-239	11	4	elevated	elevated	ADJ
egc-239	11	5	levels	level	NOUN
egc-239	11	6	of	of	ADP
egc-239	11	7	pro	pro	ADJ
egc-239	11	8	-	-	ADJ
egc-239	11	9	inflammatory	inflammatory	ADJ
egc-239	11	10	cytokines	cytokine	NOUN
egc-239	11	11	il-8	il-8	PUNCT
egc-239	11	12	and	and	CCONJ
egc-239	11	13	il-17a	il-17a	PROPN
egc-239	11	14	,	,	PUNCT
egc-239	11	15	coupled	couple	VERB
egc-239	11	16	with	with	ADP
egc-239	11	17	reduced	reduce	VERB
egc-239	11	18	ifnγ	ifnγ	NOUN
egc-239	11	19	levels	level	NOUN
egc-239	11	20	,	,	PUNCT
egc-239	11	21	suggest	suggest	VERB
egc-239	11	22	that	that	SCONJ
egc-239	11	23	children	child	NOUN
egc-239	11	24	with	with	ADP
egc-239	11	25	jra	jra	PROPN
egc-239	11	26	,	,	PUNCT
egc-239	11	27	especially	especially	ADV
egc-239	11	28	those	those	PRON
egc-239	11	29	with	with	ADP
egc-239	11	30	the	the	DET
egc-239	11	31	seropositive	seropositive	ADJ
egc-239	11	32	form	form	NOUN
egc-239	11	33	,	,	PUNCT
egc-239	11	34	experience	experience	NOUN
egc-239	11	35	heightened	heighten	VERB
egc-239	11	36	inflammatory	inflammatory	ADJ
egc-239	11	37	responses	response	NOUN
egc-239	11	38	.	.	PUNCT
egc-239	12	1	these	these	DET
egc-239	12	2	findings	finding	NOUN
egc-239	12	3	highlight	highlight	VERB
egc-239	12	4	the	the	DET
egc-239	12	5	importance	importance	NOUN
egc-239	12	6	of	of	ADP
egc-239	12	7	cytokine	cytokine	ADJ
egc-239	12	8	profiling	profiling	NOUN
egc-239	12	9	for	for	ADP
egc-239	12	10	understanding	understand	VERB
egc-239	12	11	disease	disease	NOUN
egc-239	12	12	severity	severity	NOUN
egc-239	12	13	and	and	CCONJ
egc-239	12	14	guiding	guide	VERB
egc-239	12	15	therapeutic	therapeutic	ADJ
egc-239	12	16	interventions	intervention	NOUN
egc-239	12	17	.	.	PUNCT
egc-239	13	1	https://eglobalcongress.com/index.php/egc	https://eglobalcongress.com/index.php/egc	ADJ
egc-239	13	2	eglobal	eglobal	PROPN
egc-239	13	3	congress	congress	PROPN
egc-239	13	4	hosted	host	VERB
egc-239	13	5	online	online	ADV
egc-239	13	6	from	from	ADP
egc-239	13	7	dubai	dubai	PROPN
egc-239	13	8	,	,	PUNCT
egc-239	13	9	u.	u.	PROPN
egc-239	13	10	a.	a.	PROPN
egc-239	13	11	e.	e.	PROPN
egc-239	13	12	,	,	PUNCT
egc-239	13	13	e	e	PROPN
egc-239	13	14	conference	conference	NOUN
egc-239	13	15	.	.	PUNCT
egc-239	14	1	date	date	NOUN
egc-239	14	2	:	:	PUNCT
egc-239	14	3	29th	29th	ADJ
egc-239	14	4	september	september	PROPN
egc-239	14	5	2024	2024	NUM
egc-239	14	6	website	website	NOUN
egc-239	14	7	:	:	PUNCT
egc-239	14	8	https://eglobalcongress.com/index.php/egc	https://eglobalcongress.com/index.php/egc	PROPN
egc-239	14	9	issn	issn	PROPN
egc-239	14	10	(	(	PUNCT
egc-239	14	11	e	e	NOUN
egc-239	14	12	):	):	PUNCT
egc-239	14	13	2836	2836	NUM
egc-239	14	14	-	-	SYM
egc-239	14	15	3612	3612	NUM
egc-239	14	16	13	13	NUM
egc-239	15	1	|	|	ADV
egc-239	15	2	p	p	NOUN
egc-239	15	3	a	a	DET
egc-239	15	4	g	g	NOUN
egc-239	15	5	e	e	NOUN
egc-239	15	6	reference	reference	NOUN
egc-239	15	7	list	list	NOUN
egc-239	15	8	:	:	PUNCT
egc-239	15	9	1	1	X
egc-239	15	10	.	.	X
egc-239	15	11	abramkin	abramkin	PROPN
egc-239	15	12	aa	aa	PROPN
egc-239	15	13	,	,	PUNCT
egc-239	15	14	lisitsyna	lisitsyna	PROPN
egc-239	15	15	ta	ta	PROPN
egc-239	15	16	,	,	PUNCT
egc-239	15	17	veltishchev	veltishchev	NOUN
egc-239	15	18	dyu	dyu	ADV
egc-239	15	19	,	,	PUNCT
egc-239	15	20	seravina	seravina	PROPN
egc-239	15	21	of	of	ADP
egc-239	15	22	,	,	PUNCT
egc-239	15	23	kovalevskaya	kovalevskaya	NOUN
egc-239	15	24	ob	ob	NOUN
egc-239	15	25	,	,	PUNCT
egc-239	15	26	nasonov	nasonov	PROPN
egc-239	15	27	el	el	PROPN
egc-239	15	28	.	.	PUNCT
egc-239	16	1	the	the	DET
egc-239	16	2	influence	influence	NOUN
egc-239	16	3	of	of	ADP
egc-239	16	4	synthetic	synthetic	ADJ
egc-239	16	5	disease	disease	NOUN
egc-239	16	6	-	-	PUNCT
egc-239	16	7	modifying	modify	VERB
egc-239	16	8	antiinflammatory	antiinflammatory	NOUN
egc-239	16	9	drugs	drug	NOUN
egc-239	16	10	,	,	PUNCT
egc-239	16	11	genetically	genetically	ADV
egc-239	16	12	engineered	engineer	VERB
egc-239	16	13	biological	biological	ADJ
egc-239	16	14	agents	agent	NOUN
egc-239	16	15	and	and	CCONJ
egc-239	16	16	psychopharmacological	psychopharmacological	NOUN
egc-239	16	17	therapy	therapy	NOUN
egc-239	16	18	on	on	ADP
egc-239	16	19	the	the	DET
egc-239	16	20	dynamics	dynamic	NOUN
egc-239	16	21	of	of	ADP
egc-239	16	22	mental	mental	ADJ
egc-239	16	23	disorders	disorder	NOUN
egc-239	16	24	in	in	ADP
egc-239	16	25	patients	patient	NOUN
egc-239	16	26	with	with	ADP
egc-239	16	27	rheumatoid	rheumatoid	NOUN
egc-239	16	28	arthritis	arthritis	NOUN
egc-239	16	29	//	//	NOUN
egc-239	16	30	scientific	scientific	ADJ
egc-239	16	31	and	and	CCONJ
egc-239	16	32	practical	practical	ADJ
egc-239	16	33	rheumatology	rheumatology	NOUN
egc-239	16	34	.	.	PUNCT
egc-239	17	1	2017	2017	NUM
egc-239	17	2	—	—	PUNCT
egc-239	17	3	no	no	NOUN
egc-239	17	4	.	.	NOUN
egc-239	18	1	55	55	NUM
egc-239	18	2	—	—	PUNCT
egc-239	18	3	vol	vol	NOUN
egc-239	18	4	.	.	PROPN
egc-239	18	5	4	4	NUM
egc-239	18	6	—	—	PUNCT
egc-239	18	7	p.	p.	NOUN
egc-239	18	8	393—402	393—402	NOUN
egc-239	18	9	.	.	PUNCT
egc-239	19	1	2	2	NUM
egc-239	19	2	.	.	X
egc-239	19	3	avdeeva	avdeeva	VERB
egc-239	19	4	as	as	ADP
egc-239	19	5	,	,	PUNCT
egc-239	19	6	artyukhov	artyukhov	ADJ
egc-239	19	7	as	as	ADP
egc-239	19	8	,	,	PUNCT
egc-239	19	9	dashinimaev	dashinimaev	PROPN
egc-239	19	10	eb	eb	PROPN
egc-239	19	11	,	,	PUNCT
egc-239	19	12	cherkasova	cherkasova	PROPN
egc-239	19	13	mv	mv	PROPN
egc-239	19	14	,	,	PUNCT
egc-239	19	15	nasonov	nasonov	PROPN
egc-239	19	16	el	el	PROPN
egc-239	19	17	.	.	PUNCT
egc-239	20	1	dynamics	dynamic	NOUN
egc-239	20	2	of	of	ADP
egc-239	20	3	cytokine	cytokine	ADJ
egc-239	20	4	profile	profile	NOUN
egc-239	20	5	parameters	parameter	NOUN
egc-239	20	6	against	against	ADP
egc-239	20	7	the	the	DET
egc-239	20	8	background	background	NOUN
egc-239	20	9	of	of	ADP
egc-239	20	10	the	the	DET
egc-239	20	11	use	use	NOUN
egc-239	20	12	of	of	ADP
egc-239	20	13	a	a	DET
egc-239	20	14	biosimilar	biosimilar	NOUN
egc-239	20	15	of	of	ADP
egc-239	20	16	rituximab	rituximab	NOUN
egc-239	20	17	(	(	PUNCT
egc-239	20	18	acellbia	acellbia	NOUN
egc-239	20	19	,	,	PUNCT
egc-239	20	20	biocad	biocad	PROPN
egc-239	20	21	)	)	PUNCT
egc-239	20	22	and	and	CCONJ
egc-239	20	23	the	the	DET
egc-239	20	24	original	original	ADJ
egc-239	20	25	drug	drug	NOUN
egc-239	20	26	(	(	PUNCT
egc-239	20	27	mabthera	mabthera	NOUN
egc-239	20	28	,	,	PUNCT
egc-239	20	29	f.	f.	PROPN
egc-239	20	30	hoffmann	hoffmann	PROPN
egc-239	20	31	-	-	PUNCT
egc-239	20	32	la	la	PROPN
egc-239	20	33	roche	roche	PROPN
egc-239	20	34	ltd	ltd	PROPN
egc-239	20	35	.	.	PROPN
egc-239	20	36	,	,	PUNCT
egc-239	20	37	switzerland	switzerland	PROPN
egc-239	20	38	)	)	PUNCT
egc-239	20	39	in	in	ADP
egc-239	20	40	the	the	DET
egc-239	20	41	treatment	treatment	NOUN
egc-239	20	42	of	of	ADP
egc-239	20	43	rheumatoid	rheumatoid	NOUN
egc-239	20	44	arthritis	arthritis	NOUN
egc-239	20	45	//	//	NOUN
egc-239	20	46	scientific	scientific	ADJ
egc-239	20	47	and	and	CCONJ
egc-239	20	48	practical	practical	ADJ
egc-239	20	49	rheumatology	rheumatology	NOUN
egc-239	20	50	.	.	PUNCT
egc-239	21	1	2019	2019	NUM
egc-239	21	2	—	—	PUNCT
egc-239	21	3	no	no	NOUN
egc-239	21	4	.	.	NOUN
egc-239	21	5	57	57	NUM
egc-239	21	6	—	—	PUNCT
egc-239	21	7	vol	vol	NOUN
egc-239	21	8	.	.	NOUN
egc-239	21	9	1	1	NUM
egc-239	21	10	—	—	PUNCT
egc-239	21	11	p.	p.	NOUN
egc-239	21	12	46—55	46—55	NUM
egc-239	21	13	.	.	PUNCT
egc-239	22	1	3	3	X
egc-239	22	2	.	.	X
egc-239	22	3	avdeeva	avdeeva	VERB
egc-239	22	4	as	as	SCONJ
egc-239	22	5	,	,	PUNCT
egc-239	22	6	cherkasova	cherkasova	PROPN
egc-239	22	7	mv	mv	PROPN
egc-239	22	8	,	,	PUNCT
egc-239	22	9	kusevich	kusevich	X
egc-239	22	10	da	da	X
egc-239	22	11	,	,	PUNCT
egc-239	22	12	rybakova	rybakova	X
egc-239	22	13	vv	vv	NOUN
egc-239	22	14	,	,	PUNCT
egc-239	22	15	nasonov	nasonov	NOUN
egc-239	22	16	el	el	PROPN
egc-239	22	17	.	.	PUNCT
egc-239	23	1	immunological	immunological	ADJ
egc-239	23	2	effects	effect	NOUN
egc-239	23	3	of	of	ADP
egc-239	23	4	a	a	DET
egc-239	23	5	biosimilar	biosimilar	NOUN
egc-239	23	6	of	of	ADP
egc-239	23	7	rituximab	rituximab	NOUN
egc-239	23	8	(	(	PUNCT
egc-239	23	9	acellbia	acellbia	NOUN
egc-239	23	10	,	,	PUNCT
egc-239	23	11	biocad	biocad	PROPN
egc-239	23	12	)	)	PUNCT
egc-239	23	13	in	in	ADP
egc-239	23	14	patients	patient	NOUN
egc-239	23	15	with	with	ADP
egc-239	23	16	rheumatoid	rheumatoid	NOUN
egc-239	23	17	arthritis	arthritis	NOUN
egc-239	23	18	//	//	NOUN
egc-239	23	19	scientific	scientific	ADJ
egc-239	23	20	and	and	CCONJ
egc-239	23	21	practical	practical	ADJ
egc-239	23	22	rheumatology	rheumatology	NOUN
egc-239	23	23	.	.	PUNCT
egc-239	24	1	2018	2018	NUM
egc-239	24	2	—	—	PUNCT
egc-239	25	1	no	no	INTJ
egc-239	25	2	.	.	NOUN
egc-239	26	1	56	56	NUM
egc-239	26	2	—	—	PUNCT
egc-239	26	3	vol	vol	NOUN
egc-239	26	4	.	.	PROPN
egc-239	26	5	5	5	NUM
egc-239	26	6	—	—	PUNCT
egc-239	26	7	p.	p.	NOUN
egc-239	26	8	556—563	556—563	PROPN
egc-239	26	9	.	.	PUNCT
egc-239	27	1	4	4	X
egc-239	27	2	.	.	X
egc-239	27	3	beketova	beketova	PROPN
egc-239	27	4	tv	tv	NOUN
egc-239	27	5	,	,	PUNCT
egc-239	27	6	arsenyev	arsenyev	PROPN
egc-239	27	7	ev	ev	INTJ
egc-239	27	8	.	.	PUNCT
egc-239	27	9	interleukin	interleukin	NOUN
egc-239	27	10	5	5	NUM
egc-239	27	11	—	—	PUNCT
egc-239	27	12	a	a	DET
egc-239	27	13	new	new	ADJ
egc-239	27	14	target	target	NOUN
egc-239	27	15	for	for	ADP
egc-239	27	16	the	the	DET
egc-239	27	17	therapy	therapy	NOUN
egc-239	27	18	of	of	ADP
egc-239	27	19	eosinophilic	eosinophilic	ADJ
egc-239	27	20	granulomatosis	granulomatosis	NOUN
egc-239	27	21	with	with	ADP
egc-239	27	22	polyangiitis	polyangiitis	PROPN
egc-239	27	23	//	//	SYM
egc-239	27	24	scientific	scientific	ADJ
egc-239	27	25	and	and	CCONJ
egc-239	27	26	practical	practical	ADJ
egc-239	27	27	rheumatology	rheumatology	NOUN
egc-239	27	28	.	.	PUNCT
egc-239	28	1	2020	2020	NUM
egc-239	28	2	—	—	PUNCT
egc-239	28	3	№	№	NOUN
egc-239	28	4	58	58	NUM
egc-239	28	5	—	—	PUNCT
egc-239	28	6	vol	vol	NOUN
egc-239	28	7	.	.	NOUN
egc-239	28	8	3	3	NUM
egc-239	28	9	—	—	PUNCT
egc-239	28	10	p.	p.	NOUN
egc-239	28	11	321—329	321—329	PROPN
egc-239	28	12	.	.	PUNCT
egc-239	29	1	5	5	NUM
egc-239	29	2	.	.	X
egc-239	29	3	beketova	beketova	PROPN
egc-239	29	4	tv	tv	PROPN
egc-239	29	5	,	,	PUNCT
egc-239	29	6	blank	blank	ADJ
egc-239	29	7	lm	lm	PROPN
egc-239	29	8	,	,	PUNCT
egc-239	29	9	lila	lila	PROPN
egc-239	29	10	am	be	AUX
egc-239	29	11	.	.	PUNCT
egc-239	30	1	covid-19	covid-19	PROPN
egc-239	30	2	in	in	ADP
egc-239	30	3	a	a	DET
egc-239	30	4	patient	patient	NOUN
egc-239	30	5	with	with	ADP
egc-239	30	6	ancaassociated	ancaassociate	VERB
egc-239	30	7	systemic	systemic	ADJ
egc-239	30	8	vasculitis	vasculitis	NOUN
egc-239	30	9	receiving	receive	VERB
egc-239	30	10	anti	anti	ADJ
egc-239	30	11	-	-	ADJ
egc-239	30	12	b	b	ADJ
egc-239	30	13	-	-	PUNCT
egc-239	30	14	cell	cell	NOUN
egc-239	30	15	therapy	therapy	NOUN
egc-239	30	16	with	with	ADP
egc-239	30	17	rituximab	rituximab	NOUN
egc-239	30	18	//	//	NUM
egc-239	30	19	scientific	scientific	ADJ
egc-239	30	20	and	and	CCONJ
egc-239	30	21	practical	practical	ADJ
egc-239	30	22	rheumatology	rheumatology	NOUN
egc-239	30	23	.	.	PUNCT
egc-239	31	1	2020	2020	NUM
egc-239	31	2	—	—	PUNCT
egc-239	31	3	№	№	NOUN
egc-239	31	4	58	58	NUM
egc-239	31	5	—	—	PUNCT
egc-239	31	6	vol	vol	NOUN
egc-239	31	7	.	.	PROPN
egc-239	31	8	4	4	NUM
egc-239	31	9	—	—	PUNCT
egc-239	31	10	p.	p.	NOUN
egc-239	31	11	456—462	456—462	PROPN
egc-239	31	12	.	.	PUNCT
egc-239	32	1	https://eglobalcongress.com/index.php/egc	https://eglobalcongress.com/index.php/egc	PROPN